What happened with CCEL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cryo-Cell International Inc. processes, tests and freezes newborns’ umbilical cord blood and stores cord tissue so families can preserve stem cells for potential future use. Families pay for processing, testing and the first year of storage, then pay annually unless they choose prepaid long-term storage. This family service accounts for nearly all revenue. The business depends on enrolling new families, collecting recurring storage fees and keeping specimens continuously frozen.
Its smaller public cord blood bank supplies units for transplants through the National Marrow Donor Program (NMDP), which distributes them to transplant centers and reimburses Cryo-Cell on a cost-recovery basis. These units are distributed under an investigational new drug application maintained by NMDP.
Plans to expand into infusion clinics and biopharmaceutical manufacturing through a Duke University license are paused following Duke’s termination notice and an unresolved dispute. Manufacturing under those plans would require FDA approval of biologics license applications; these remain planned businesses, not established sources of income.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cryo-Cell’s results hinge on families signing up for cord blood banking and paying recurring storage fees, while its dispute with Duke University affects potential expansion beyond banking.
No upcoming items to show.
Earnings, filings and other dated events show up here once their dates are set.
